Palisade Bio, Inc. Common Stock (PALI) Stock
Key stats
- Market cap
- $209.99M
- Price / Earnings ratio
- -6.2x
- EPS (TTM)
- $0.60
- Volume
- Loading
- 52-week high
- $2.86
- 52-week low
- $1.08
Source: third-party data provider, as of November 13, 2026
Compare with PALI
Recent news

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
PALI

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
PALI

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
PALI

Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
PALI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 39.82
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.01
- SMA 50
- $1.52
- Price below SMA 50
- EMA 50
- $1.46
- Price below EMA 50
- SMA 200
- $1.83
- Price below SMA 200
- EMA 200
- $1.76
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
PALI

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
PALI

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
PALI

Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
PALI
News tone: automated (AI) classification of the article's content, not a price prediction.
About Palisade Bio, Inc. Common Stock
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. J. D. Finley | CEO, CFO & Director | 1958 |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | President & Chief Medical Officer | 1977 |
| Dr. Joerg Heyer Ph.D. | Head of Translational Science & Medicine | — |
| Dr. James Izanec M.D. | VP & Head of Clinical Development | — |
| Mr. Daniel J. Larkins | Head of Global Regulatory Affairs | — |
| Mr. Adarsh Patel M.B.A., M.S. | Head of Chemistry, Manufacturing & Controls | — |
| Ms. Dawn Louro | VP & Head of Clinical Operations | — |
| Mr. Ryker Willie | Senior VP of Finance & Corporate Controller | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 39.82
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.01
- SMA 50
- $1.52
- Price below SMA 50
- EMA 50
- $1.46
- Price below EMA 50
- SMA 200
- $1.83
- Price below SMA 200
- EMA 200
- $1.76
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $5.00
- Average
- $9.00
- High
- $16.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.6 | +6.4 | +6.5 | +0.5 | -3.6 | +0.5 | -31.1 | -18.9 | +4.5 |



